General Information


Exagen is dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention. We have developed and are commercializing a portfolio of innovative testing products under our AVISE® brand, several of which are based on our proprietary Cell-Bound Complement Activation Products, or CB-CAPs, technology. CB-CAPs assess the activation of the complement system, a biological pathway that is widely implicated across many autoimmune and autoimmune-related diseases, including systemic lupus erythematosus, or SLE. Our goal is to enable rheumatologists to improve care for patients through the differential diagnosis, prognosis and monitoring of complex autoimmune and autoimmune-related diseases, including SLE and rheumatoid arthritis, or RA.

Employees: 114
Founded: 2002
Contact Information
Address 1261 Liberty Way, Suite C, Vista, CA 92081, US
Phone Number (760) 560-1501
Web Address http://www.exagen.com
View Prospectus: Exagen
Financial Information
Market Cap $168.5mil
Revenues $37.6 mil (last 12 months)
Net Income $-18.5 mil (last 12 months)
IPO Profile
Symbol XGN
Exchange NASDAQ
Shares (millions): 3.6
Price range $14.00 - $14.00
Est. $ Volume $50.0 mil
Manager / Joint Managers Cowen and Company/ Cantor Fitzgerald/ William Blair
CO-Managers -
Expected To Trade: 9/19/2019
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change